Tanfac Inds. Q1 FY27 Earnings Call — Analysis (BSE: 506854)

TANFAC turns net debt-free and guides for 30% FY27 revenue growth, 60% in FY28, driven by HFC-32 ramp-up and strategic expansions.

3 Aug 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Revenue from operations ₹187 Cr ( +6.3% YoY ) . New guidance — FY27 fy27 revenue growth at least 30% . New story: Value chain climbing .

Results

Revenue ₹187 Cr +6.3% YoY; EBITDA margin 15.3% down YoY on higher fuel/power and sulphur costs; PAT ₹16.8 Cr vs ₹19.4 Cr YoY.

Financial highlights

Guidance

FY27 revenue growth of at least 30% and FY28 over 60%; HFC-32 commissioning by Q3FY27, with EBITDA margin seen reaching 25% in FY28.

What management committed to

• Revenue for FY27 will grow by at least 30% compared to FY26. — at least 30%, FY27
• Revenue for FY28 will grow by over 60% compared to FY27. — over 60%, FY28
• EBITDA margin will improve to the range of 16% to 19% from Q2 FY27 onwards. — 16% to 19%, Q2FY27
• EBITDA margin in FY28 will be around 25%, driven by the [HFC-32] project. — around 25%, FY28
• The [HFC-32 refrigerant gas] plant will be commissioned by the end of Q3 FY27 (November-December 2026). — Q3FY27
• The [HFC-32] project will not exceed the INR395 crore budget; no cost overruns expected. — INR395 Cr, Q3FY27
• [HFC-32] plant utilization in Q4 FY27 will be 65% to 70%. — 65% to 70%, Q4FY27
• [HFC-32] plant utilization in FY28 will be 80% to 85% on a conservative basis. — 80% to 85%, FY28
• Revenue from the [HFC-32] project at full capacity is expected to be approximately ₹900-1,000 crore. — ₹900-1,000 Cr, when fully ramped
• Near-term capex of approximately ₹300 crore (solar DHF expansion, AHF 20-30 KTA, electronic grade) will start after [HFC-32] project commissioning. — ~₹300 Cr, Q4FY27
• AHF capacity will be expanded by 20,000 to 30,000 metric tonnes per annum and commissioned by FY28. — 20-30 KTA, FY28
• Solar grade DHF capacity will be expanded to almost double the existing capacity. — almost double, near future

Key themes

Value-added fluorochemical expansion with balance sheet transformation

How the narrative shifted

• Value chain climbing: Management positions TANFAC as steadily moving from commodity AHF into higher-margin, technology-driven fluorochemicals like solar DHF, HFC-32, and future electronic/fluoropolymer products.
• Contractual revenue visibility: Long-term contracts for solar DHF (through FY29) and HFC-32 (5-7 years, 65% of capacity) provide volume security and fixed EBITDA margins, reducing earnings volatility.
• Capital raise-driven transformation: Completion of INR250 Cr QIP and planned INR100 Cr preferential issue have made the company net debt-free, enabling aggressive growth capex without over-leverage.
• HFC-32 execution catalyst: The 20 KTA HFC-32 project is on schedule for Q3FY27 commissioning; it is expected to more than double revenue and substantially lift margins, acting as the primary near-term value driver.
• Near-term margin headwinds: Q1 margins were compressed by elevated sulphur and power costs linked to geopolitical factors, but the pass-through mechanism and captive power normalization should reverse the impact within a couple of quarters.
• Fluorochemical demand tailwinds: Domestic solar, refrigerant, and semiconductor growth is driving HF demand, while Chinese AHF imports remain unattractive due to regulatory and logistic hurdles, insulating domestic players.
• Execution capability strengthened: Appointment of experienced technical president and ongoing R&D investments (₹7-8 Cr capex) reinforce the company's ability to execute complex projects and develop next-gen products.

Operational commentary

• HFC-32 20 KTA project on track for commissioning in Nov-Dec '26; 60% work done, INR315 Cr of INR395 Cr committed, no cost overruns expected.
• 65% of HFC-32 capacity tied up in 5-7 year contracts at formula-based pricing, ~75% exports; another 5 KTA MoU to convert to contract soon.
• Solar grade DHF fully ramped, 80-85% contracted under long-term agreements extending through FY29; expansion plan to almost double capacity (₹30-40 Cr capex).
• Capital raise complete: INR250 Cr QIP + board-approved ~₹100 Cr preferential issue (promoter INR61 Cr); company net debt-free.
• Next capex phase (~₹300 Cr) to start post HFC-32: solar DHF expansion, AHF 20-30 KTA (₹120 Cr), and electronic grade chemicals (₹150 Cr).
• AHF capacity utilization 73% in Q1; sulfuric acid 85-88%; specialty fluorides 50%.
• R&D pipeline includes HFOs, high-performance fluoropolymers, electronic chemicals; evaluating tech tie-ups for semiconductor-grade DHF.
• AHF demand seen at 30,000-35,000 tonnes domestic; imports from China limited by regulatory/logistic barriers – no pricing pressure.
• Sulphur price surged from ₹30 to ₹105 but pass-through mechanism with 30-45 day lag; spreads maintained.
• Revenue mix currently 90% domestic, 10% exports; expected to shift to 50:50 post R-32 commissioning.

Analyst Q&A

• Q. What is the revenue outlook for FY27 and FY28?

  Company plans to achieve at least 30% growth in FY27 and over 60% in FY28, driven by HFC-32 and ramp-up of existing products.

• Q. What capex is planned beyond the HFC-32 project?

  Solar DHF expansion (~₹30-40 Cr), AHF (~₹120 Cr), electronic grade (~₹150 Cr) – total ~₹300 Cr; to start after HFC-32 commissioning.

• Q. Why lock 65% of R-32 capacity in long-term contracts rather than play spot at higher prices?

  Speed-to-market as a new entrant; contracts at $5.5/kg with cost pass-through provide fixed EBITDA margin with no volatility; remaining 35% can capture spot upside.

• Q. What specific fluoropolymer products are being targeted?

  It is a bit confidential; we are working with customers and have two-three options, but will not go into commodity-based fluoropolymers.

• Q. Will there be any teething losses or unforeseen expenses in the R-32 ramp-up?

  We are planning a vertical start-up with 1.5-2 months stabilization; confident of ramping up from February based on pilot plant experience.

View source

Research and educational content only. Not investment advice.